The development of the world’s first lung biosimulator device to investigate orally inhaled products (OIPs) under deep lung conditions – A proof of concept project.

开发世界上第一个肺部生物模拟器设备，用于在肺部深处条件下研究口服吸入产品 (OIP) - 概念验证项目。

• 批准号: 710426
• 金额: $ 11.07万
• 依托单位: PULMORPHIX LIMITED
• 依托单位国家: 英国
• 项目类别: GRD Proof of Concept
• 财政年份: 2014
• 资助国家: 英国
• 起止时间: 2014 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=710426
• 关键词: development; world; first; lung; biosimulator

Thelungs are an excellent way of delivering pharmaceutical drugs into the body to treatvarious diseases. This is because they have a large surface area, are moist and have a goodblood supply. Unlike tablet medicines, which are often slowly absorbed in the gut and thenprocessed by the liver before they can have their effect, inhaled drugs are absorbed morerapidly and exert their effects quicker. Consequently, inhaled drugs are often in smaller dosesthan oral forms, give fewer side-effects and likely to have a quicker onset of action, which canlead to better control of disease symptoms and improved patient outcomes.When pharmaceutical companies are developing inhaled drugs, for example for asthma, theyare mainly concerned with getting small-sized drug particles to reach the deepest parts of thelung where it is assumed that the particles are absorbed into the body. However, little isknown about the way the drug interacts with the lung fluids. This is important to know as thelung fluids are the initial point of contact for the drugs delivered by the inhaled route and themedia in which the drug dissolves/is released. Clearly, it is crucial to understand theinteraction between pharmaceutical drugs and the lung fluids so that drug release mechanismscan be understood. There is currently no technology available to simulate the environment ofthe deep lung so that these types of interactions can be researched.Pulmorphix is in the process of developing an innovative technology which replicates lungconditions. The objective of this research is to set up ways in which we can investigate howinhaled drugs interact with lung fluids in an environment which closely resembles that of thedeep lung. This information is of value to scientists designing inhaled drugs as theinformation generated by this technology will help them develop improved drug formulations -which will ultimately improve patient quality of life (e.g. for individuals with asthma ordiabetes).

肺是一种很好的将药物输送到体内以治疗各种疾病的方法。这是因为他们有一个大的表面积，是潮湿的，有一个良好的血液供应。与片剂药物不同，片剂药物通常在肠道中缓慢吸收，然后在发挥作用之前由肝脏处理，吸入药物吸收更快，发挥作用更快。因此，吸入药物的剂量通常比口服药物小，副作用更少，起效更快，这可以更好地控制疾病症状，改善患者的预后。当制药公司开发吸入药物时，例如哮喘，他们主要关心的是变小-大小的药物颗粒到达肺的最深处，假设颗粒被吸收到体内。然而，关于药物与肺液相互作用的方式知之甚少。这一点很重要，因为肺部液体是通过吸入途径输送药物的初始接触点，也是药物溶解/释放的介质。显然，了解药物和肺液之间的相互作用是至关重要的，这样才能了解药物释放机制。目前还没有技术可以模拟肺部深处的环境，以便研究这些类型的相互作用。Pulmorphix正在开发一种复制肺部条件的创新技术。这项研究的目的是建立一种方法，使我们能够研究吸入药物如何在一个与肺深部非常相似的环境中与肺液相互作用。这些信息对于设计吸入药物的科学家来说很有价值，因为这项技术产生的信息将帮助他们开发改进的药物配方，这最终将提高患者的生活质量（例如，对于哮喘或糖尿病患者）。